Last reviewed · How we verify

Saglik Bilimleri Universitesi Gulhane Tip Fakultesi — Portfolio Competitive Intelligence Brief

Saglik Bilimleri Universitesi Gulhane Tip Fakultesi pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
NSAID's NSAID's marketed Non-steroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Pain management, Inflammation, Rheumatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. IBSA Institut Biochimique SA · 1 shared drug class
  3. Insel Gruppe AG, University Hospital Bern · 1 shared drug class
  4. Pfizer · 1 shared drug class
  5. Rabin Medical Center · 1 shared drug class
  6. Shijiazhuang Yiling Pharmaceutical Co. Ltd · 1 shared drug class
  7. Takeda · 1 shared drug class
  8. Thomas Jefferson University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Saglik Bilimleri Universitesi Gulhane Tip Fakultesi:

Cite this brief

Drug Landscape (2026). Saglik Bilimleri Universitesi Gulhane Tip Fakultesi — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/saglik-bilimleri-universitesi-gulhane-tip-fakultesi. Accessed 2026-05-16.

Related